Metabolic Syndrome

Endocrinology: Adult and Pediatric

Volumn 1-2, Issue , 2015, Pages 752-769.e7

  Ruderman, Neil B ^a   Shulman, Gerald I ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85046759485     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-18907-1.00043-3     Document Type: Chapter

References (305)

1. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
2. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002, 106:286-288.
3. Richter E.A., Ruderman N.B. AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J 2009, 418(2):261-275.
4. Kissebah A.H., Vydelingum N., Murray R., et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982, 54:254-260.
5. Bernstein R.S., Grant N., Kipnis D.M. Hyperinsulinemia and enlarged adipocytes in patients with endogenous hyperlipoproteinemia without obesity or diabetes mellitus. Diabetes 1975, 24:207-213.
6. Ruderman N.B., Schneider S.H., Berchtold P. The "metabolically-obese," normal-weight individual. Am J Clin Nutr 1981, 34:1617-1621.
7. Petersen K.F., Dufour S., Befroy D., et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004, 350:664-671.
8. Ruderman N., Chisholm D., Pi-Sunyer X., et al. The metabolically obese, normal-weight individual revisited. Diabetes 1998, 47:699-713.
9. Festa A., D'Agostino R., Howard G., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
10. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813-823.
11. Schmidt M.I., Duncan B.B., Sharrett A.R., et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet 1999, 353:1649-1652.
12. Juhan-Vague I., Alessi M.C., Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991, 34:457-462.
13. Sakkinen P., Geffken D., Cushman M., et al. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 2001, 153:242-250.
14. Reaven G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003, 88:2399-2403.
15. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
16. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
17. Grundy S.M. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008, 28:629-636.
18. Alberti G., Zimmet P., Shaw J., et al. Type 2 diabetes in the young: the evolving epidemic: the International Diabetes Federation Consensus Workshop. Diabetes Care 2004, 27:1798-1811.
19. Weiss R., Dufour S., Taksali S.E., et al. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 2003, 362:951-957.
20. Weiss R., Dziura J., Burgert T.S., et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004, 350:2362-2374.
21. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
22. Grundy S.M. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007, 92:399-404.
23. Kahn R., Buse J., Ferrannini E., et al. The metabolic syndrome: time for a critical appraisal: Joint Statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
24. Beltrán-sánchez H., Harhay M.O., Harhay M.M., Mcelligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol 2013, 62(8):697-703.
25. Dieterle P., Fehm H., Stroder W., et al. Asymptomatic diabetes mellitus in hypertensive patients of normal weight. Glucose tolerance and serum levels of insulin and nonesterified fatty acids in essential hypertension. Ger Med Mon 1968, 13:478-483.
26. Modan M., Halkin H., Almog S., et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 1985, 75:809-817.
27. Stern M.P. The insulin resistance syndrome. International textbook of diabetes mellitus 1997, 255-283. John Wiley & Sons, New York. K.G.M.M. Alberti (Ed.).
28. Flier J.S. An overview of insulin resistance. Insulin resistance 1993, 1-8. Wiley, Chichester, UK. D.E. Moller (Ed.).
29. Himsworth H. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936, 1:127.
30. Himsworth H.P., Kerr R.B. Insulin sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 1939, 4:119-152.
31. Himsworth H.P. The syndrome of diabetes mellitus and its causes. Lancet 1949, 1:465-473.
32. Yalow R.S., Berson S.A. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960, 39:1157-1175.
33. Berson S.A., Yalow R.S. Plasma insulin in health and disease. Am J Med 1961, 31:874-881.
34. Karam J.H., Grodsky G.M., Forsham P.H. Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes 1963, 12:197-204.
35. Bjorntorp P. The relationship between obesity and diabetes. International textbook of diabetes mellitus 1997, 612-627. John Wiley & Sons, New York. K.G.M.M. Alberti (Ed.).
36. Davidson P.C., Albrink M.J. Insulin resistance in hyperglyceridemia. Metabolism 1965, 14:1059-1070.
37. DeFronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
38. Malherbe C., Heller F., de Gasparo M., et al. Insulin response during prolonged glucose infusion. J Clin Endocrinol Metab 1970, 30:535-538.
39. Ruderman N.B., Berchtold P., Schneider S. Obesity-associated disorders in normal-weight individuals: some speculations. Int J Obes 1982, 6(Suppl 1):151-157.
40. Ruderman N.B., Haudenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984, 26:373-412.
41. Petersen K.F., Dufour S., Feng J., et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 2006, 103:18273-18277.
42. Bays H., Mandarino L., DeFronzo R.A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004, 89:463-478.
43. Lapidus L., Bengtsson C., Larsson B., et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg. Sweden, Br Med J (Clin Res Ed) 1984, 289:1257-1261.
44. Larsson B., Svardsudd K., Welin L., et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) 1984, 288:1401-1404.
45. Beck-Nielsen H., Groop L.C. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994, 94:1714-1721.
46. Perseghin G., Price T.B., Petersen K.F., et al. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 1996, 335:1357-1362.
47. Rothman D.L., Magnusson I., Cline G., et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1995, 92:983-987.
48. Ferrari P., Weidmann P., Shaw S., et al. Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991, 91:589-596.
49. Ruderman N.B., Schneider S.H., Berchtold P. The "metabolically-obese," normal-weight individual. Am J Clin Nutr 1981, 34:1617-1621.
50. Werbin B., Tamir I., Heldenberg D., et al. Immunoreactive insulin and glucose response to oral glucose in offspring of patients with endogenous hypertriglyceridaemia. Clin Chim Acta 1977, 76:35-40.
51. Despres J.P., Lamarche B., Mauriege P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
52. Ducimetiere P., Eschwege E., Papoz L., et al. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980, 19:205-210.
53. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979, 2:131-141.
54. Welborn T.A., Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979, 2:154-160.
55. Nesto R.W., Phillips R.T., Kett K.G., et al. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 1988, 108:170-175.
56. UKPDS Complications of newly diagnosed type 2 diabetes patients and their association with different clinical and biochemical risk factors. Diab Res 1990, 13:1-11.
57. Uusitupa M.I., Niskanen L.K., Siitonen O., et al. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993, 36:1175-1184.
58. Jarrett R.J., McCartney P., Keen H. The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982, 22:79-84.
59. Haffner S.M., Stern M.P., Hazuda H.P., et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 1990, 263:2893-2898.
60. Panzer C., Brieke A., Ruderman N.B. Prevention of type 2 diabetes and its macrovascular complications: whom, when and how should we treat?. Curr Opin Endocrinol Diabetes 2003, 10:219-236.
61. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
62. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance, The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
63. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
64. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796-2803.
65. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
66. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008-1017.
67. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
68. Dhindsa G., Bhatia R., Dhindsa M., et al. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. J Postgrad Med 2004, 50:140-144.
69. Sam S., Dunaif A. Polycystic ovary syndrome: syndrome XX?. Trends Endocrinol Metab 2003, 14:365-370.
70. McGarry J.D. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 1992, 258:766-770.
71. Almind K., Accili D., Kahn C.R. Knockout mice as a tool to the understanding of diabetes. Diabetes mellitus: a fundamental and clinical text 2004, 245-254. Lippincott, Philadelphia. D. LeRoith, S.I. Taylor, J.M. Olefsky (Eds.).
72. White M.F. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002, 283:E413-E422.
73. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176.
74. Reaven G.M. The fourth musketeer-from Alexandre Dumas to Claude Bernard. Diabetologia 1995, 38:3-13.
75. Ruderman N., Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 2004, 3:340-351.
76. Ruderman N.B., Saha A.K., Vavvas D., et al. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 1999, 276:E1-E18.
77. Randle P.J., Garland P.B., Hales C.N., et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
78. Randle P.J., Newsholme E.A., Garland P.B. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 1964, 93:652-665.
79. Randle P.J., Garland P.B., Newsholme E.A., et al. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann N Y Acad Sci 1965, 131:324-333.
80. Randle P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 1998, 14:263-283.
81. Ruderman N.B., Toews C.J., Shafrir E. Role of free fatty acids in glucose homeostasis. Arch Intern Med 1969, 123:299-313.
82. Ruderman N.B., Houghton C.R.S., Hems R.A. Evaluation of the isolated perfused rat hindquarter for the study of muscle metabolism. Biochem J 1971, 124(3):639-651.
83. Ruderman N.B., Saha A.K., Vavvas D., et al. Malonyl CoA as a metabolic switch and a regulator of insulin sensitivity. Skeletal muscle metabolism in exercise and diabetes 1998, 263-270. Plenum. E.A. Richter, H. Galbo, B. Kiens (Eds.).
84. Boden G., Jadali F., White J., et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 1991, 88:960-966.
85. Roden M., Price T.B., Perseghin G., et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996, 97:2859-2865.
86. Dresner A., Laurent D., Marcucci M., et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999, 103:253-259.
87. Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002, 32(Suppl 3):14-23.
88. Ellis B.A., Poynten A., Lowy A.J., et al. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol Endocrinol Metab 2000, 279:E554-E560.
89. Griffin M.E., Marcucci M.J., Cline G.W., et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999, 48:1270-1274.
90. Itani S.I., Ruderman N.B., Schmieder F., et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 2002, 51:2005-2011.
91. Boden G., She P., Mozzoli M., et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 2005, 54:3458-3465.
92. Lam T.K., van de Werve G., Giacca A. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites. Am J Physiol 2003, 284:E281-E290.
93. Samuel V.T., Liu Z.X., Qu X., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004, 279:32345-32353.
94. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
95. Considine R., Nyce M.R., Allen L.E., et al. Protein kinase C is increased in the liver of humans and rats with non-insulin-dependent diabetes mellitus: an alteration not due to hyperglycemia. J Clin Invest 1995, 95:2938-2944.
96. Cortright R.N., Azevedo J.L., Zhou Q., et al. Protein kinase C modulates insulin action in human skeletal muscle. Am J Physiol Endocrinol Metab 2000, 278:E553-E562.
97. Boden G. Free fatty acids as a target for therapy. Curr Opin Endocrinol Diab 2004, 11:258-263.
98. Reaven G. Insulin resistance and its consequences type 2 diabetes mellitus and the insulin resistance syndrome. Diabetes melliltus: a fundamental and clinical text 2004, 899-915. Lippincott Williams & Wilkins. D. Leroith, S.I. Taylor, J.M. Olefsky (Eds.).
99. Puri V., Ranjit S., Konda S., et al. Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc Natl Acad Sci U S A 2008, 105:7833-7838.
100. Perseghin G., Ghosh S., Gerow K., et al. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 1997, 46:1001-1009.
101. McGarry J.D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18.
102. Heydrick S.J., Ruderman N.B., Kurowski T.G., et al. Enhanced stimulation of diacylglycerol and lipid synthesis by insulin in denervated muscle. Altered protein kinase C activity and possible link to insulin resistance. Diabetes 1991, 40:1707-1711.
103. Saha A.K., Kurowski T.G., Colca J.R., et al. Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. Am J Physiol 1994, 267:E95-E101.
104. Dobbins R.L., Szczepaniak L.S., Bentley B., et al. Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 2001, 50:123-130.
105. Abu-Elheiga L., Matzuk M.M., Abo-Hashema K.A.H., et al. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001, 291:2613-2616.
106. Choi C.S., Savage D.B., Abu-Elheiga L., et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci U S A 2007, 104:1648-16485.
107. Harwood H.J., Petras S.F., Shelly L.D., et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 2003, 278:3709-37111.
108. Savage D.B., Choi C.S., Samuel V.T., et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 2006, 116:817-824.
109. Ravussin E., Swinburn B.A. Energy expenditure and obesity. Diab Rev 1996, 4:403-422.
110. Ruderman N.B., Saha A.K., Kraegen E.W. Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 2003, 144:5166-5171.
111. Etgen G.J., Oldham B.A. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 2000, 49:684-688.
112. Faldt J., Wernstedt I., Fitzgerald S.M., et al. Reduced exercise endurance in interleukin-6-deficient mice. Endocrinology 2004, 145:2680-2686.
113. Kelly M., Keller C., Avilucea P.R., et al. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 2004, 320:449-454.
114. Yu X., McCorkle S., Wang M., et al. Leptinomimetic effects of the AMP kinase activator AICAR in leptin resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia 2004, 47:2012-2021.
115. Xu XJ, Gauthier M.S., Hess D.T., et al. Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue. J Lipid Res. 2012 2012, 53(4):792-801.
116. Gauthier M.S., O'Brien E.L., Bigornia S., et al. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem Biophys Res Commun 2011, 404(1):382-387.
117. Kelley D.E., He J., Menshikova E.V., et al. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002, 51:2944-2950.
118. Petersen K.F. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300:1140-1142.
119. Morino K., Petersen K.F., Dufour S., et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 2005, 115:3587-3593.
120. Patti M.E., Butte A.J., Crunkhorn S., et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 2003, 100:8466-8471.
121. Mootha V.K., Lindgren C.M., Eriksson K.F., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. Nat Genet 2003, 34:267-273.
122. Nyholm B., Mengel A., Nielsen S., et al. Insulin resistance in relatives of NIDDM patients: the role of physical fitness and muscle metabolism. Diabetologia 1996, 39:813-822.
123. Park H., Kaushik V.K., Constant S., et al. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP- activated protein kinase in rat tissues in response to exercise. J Biol Chem 2002, 277:32571-32577.
124. Cacicedo J.M., Gauthier M.S., Lebrasseur N.K., et al. Acute exercise activates AMPK and eNOS in the mouse aorta. Am J Physiol Heart Circ Physiol 2011, 301(4):H1255-H1265.
125. Ruderman N.B., Cacicedo J.M., Itani S., et al. MalonylCoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem Soc Trans 2003, 31:202-206.
126. Gauthier M.S., Miyoshi H., Souza S.C., et al. AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance. J Biol Chem 2008, 283:1651-16524.
127. Steinberg G.R., Schertzer J. AMPK promotes macrophage fatty acid oxidative metabolism to mitigate inflammation: implications for diabetes and cardiovascular disease. Immunol Cell Biol 2014, 92:240-345.
128. Christ-Crain M., Kola B., Lolli F., et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J 2008, 22:1672-1683.
129. Banerjee R.R., Rangwala S.M., Shapiro J.S., et al. Regulation of fasted blood glucose by resistin. Science 2004, 303:1195-1198.
130. Bergeron R., Ren J.M., Cadman K.S., et al. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab 2001, 281:E1340-E1346.
131. Jager S., Handschin C., St-Pierre J., et al. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A 2007, 104:12017-12022.
132. Suwa M., Nakano H., Kumagai S. Effects of chronic AICAR treatment on fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J Appl Physiol 2003, 95:960-968.
133. Zong H., Ren J.M., Young L.H., et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A 2002, 99:15983-15987.
134. Meigs J.B., Hu F.B., Rifai N., et al. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004, 291:1978-1986.
135. Evans J.L., Goldfine I.D., Maddux B.A., et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002, 23:599-622.
136. Gregor M.E., Yang L., Fabbrini E., et al. Endoplasmic reticulum stress is reduced in tissue of obese subjects after weight loss. Diabetes 2009, 58:693-700.
137. Salminen A., Hyttinen J.M., Kaarniranta K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J Mol Med 2011, 89(7):667-676.
138. Odegaard J.I., Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013, 339(6116):172-177.
139. Tack C.J., Stienstra R., Joosten L.A., Netea M.G. Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family. Immunol Rev 2012, 249(1):239-252.
140. Gavrilova O., Marcus-Samuels B., Graham D., et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000, 105:271-278.
141. Kim J.K., Gavrilova O., Chen Y., et al. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 2000, 275:8456-8460.
142. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004, 350:1220-1234.
143. Oral E.A., Simha V., Ruiz E., et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002, 346:570-578.
144. Petersen K.F., Oral E.A., Dufour S., et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002, 109:1345-1350.
145. Scherer P.E. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006, 55:1537-1545.
146. Lam T.K., Yoshii H., Haber C.A., et al. Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta. Am J Physiol Endocrinol Metab 2002, 283:E682-E691.
147. Steinberg G.R., Michell B.J., van Denderen B.J., et al. Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 2006, 4:465-474.
148. Fleischman A., Shoelson S.E., Bernier R., et al. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008, 31:289-294.
149. Hawley S.A., Fullerton M.D., Ross F.A., et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012, 336(6083):918-922.
150. Xu X.J., et al. What distinguishes adipose tissue of severely obese humans who are insulin sensitive and resistant?. Curr Opin Lipidol 2013, 24(1):49-56.
151. Saloranta C., Groop L. Interactions between glucose and FFA metabolism in man. Diab Metab Rev 1996, 12:15-36.
152. Rajala M.W., Scherer P.E. Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003, 144:3765-3773.
153. Tsao T.S., Tomas E., Murrey H.E., et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 2003, 278:50810-50817.
154. Lindsay R.S., Funahashi T., Hanson R.L., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360:57-58.
155. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
156. Tomas E., Tsao T.S., Saha A.K., et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 2002, 99:16309-16313.
157. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
158. Combs T.P., Berg A.H., Obici S., et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001, 108:1875-1881.
159. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
160. Kubota N., Terauchi Y., Kubota T., et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 2006, 281:8748-8755.
161. Nawrocki A.R., Rajala M.W., Tomas E., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006, 281:2654-2660.
162. Kloting N., et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010, 299(3):E506-E515.
163. Deleted in page proofs.
164. Zhang Y., Proenca R., Maffei M., et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
165. Muoio D.M., Seefeld K., Witters L.A., et al. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J 1999, 338(Pt 3):783-791.
166. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
167. Minokoshi Y., Kim Y.B., Peroni O.D., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
168. Minokoshi Y., Alquier T., Furukawa N., et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004, 428:569-574.
169. Unger R.H. Lipotoxic diseases. Annu Rev Med 2002, 53:319-336.
170. Unger R.H., Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J 2001, 15:312-321.
171. Pold R., Jensen L.S., Jessen N., et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 2005, 54:928-934.
172. Perry R.J., Zhang X.M., Zhang D., et al. Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat Med 2014, 20(7):759-763.
173. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
174. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
175. Collins T., Cybulsky M.I. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 2001, 107:255-264.
176. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
177. Hennig B., Meerarani P., Ramadass P., et al. Fatty acid-mediated activation of vascular endothelial cells. Metabolism 2000, 49:1006-1013.
178. Haffner S.M., Greenberg A.S., Weston W.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679-684.
179. Steinberg H.O., Baron A.D. Vascular function, insulin resistance and fatty acids. Diabetologia 2002, 45:623-634.
180. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799-1804.
181. Hamdy O., Ledbury S., Mullooly C., et al. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003, 26:2119-2125.
182. Hu F.B. Obesity and Cardiovascular Disease Obesity, Epidemiology 2008, Oxford University Press, New York, 174-195.
183. Cacicedo J.M., Yagihashi N., Keaney J.F., et al. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004, 324:1204-1209.
184. Kukidome D., Nishikawa T., Sonoda K., et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006, 55:120-127.
185. Ido Y., Carling D., Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 2002, 51:159-167.
186. Sun W., Lee T.S., Zhu M., et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006, 114:2655-2662.
187. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
188. Petersen K.F., Dufour S., Befroy D., et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005, 54:603-608.
189. Seppala-Lindroos A., Vehkavaara S., Hakkinen A.M., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002, 87:3023-3028.
190. Kumashiro N., Erion D., Zhang D., et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2011, 108(39):16381-16385.
191. Samuel V.T., Liu Z.X., Wang A., et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 2007, 117:739-745.
192. Peng Y., Rideout D.A., Rakita S.S., et al. Does LKB1 mediate activation of hepatic AMP-protein kinase (AMPK) and sirtuin1 (SIRT1) after Roux-en-Y gastric bypass in obese rats?. J Gastrointest Surg 2010, 14(2):221-228.
193. Poitout V., Robertson R.P. Minireview: secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143:339-342.
194. El-Assaad W., Buteau J., Peyot M.L., et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003, 144:4154-4163.
195. Prentki M., Joly E., El-Assaad W., et al. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002, 51:S405-S413.
196. Robertson R.P., Harmon J., Tran P.O., et al. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003, 52:581-587.
197. Higa M., Zhou Y.T., Ravazzola M., et al. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A 1999, 96:11513-11518.
198. Bakker S., Jzerman R., Teerlink T., et al. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure?. Atherosclerosis 2000, 148:17-21.
199. Hu F.B. Metabolic consequence of obesity, Obesity, Epidemiology 2008, Oxford University Press, New York, 149-173.
200. Yu C., Chen Y., Cline G.W., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002, 277:50230-50236.
201. Laybutt D.R., Schmitz-Peiffer C., Saha A.K., et al. Muscle lipid accumulation and protein kinase C activation in the insulin-resistant chronically glucose-infused rat. Am J Physiol 1999, 277:E1070-E1076.
202. Schmitz-Peiffer C., Browne C.L., Oakes N.D., et al. Alterations in the expression and cellular localization of protein kinase C isozymes epsilon and theta are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 1997, 46:169-178.
203. Hundal R.S., Petersen K.F., Mayerson A.B., et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002, 109:1321-1326.
204. Yuan M., Konstantopoulos N., Lee J., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta. Science 2001, 293:1673-1677.
205. Kahn B.B., Alquier T., Carling D., et al. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005, 1:15-25.
206. Morino K., Neschen S., Bilz S., et al. Muscle-specific IRS-1 Ser→Ala transgenic mice are protected from fat-induced insulin resistance in skeletal muscle. Diabetes 2008, 57:2644-2651.
207. Brown M.S., Goldstein J.L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008, 7:95-96.
208. Jacob S., Machann J., Rett K., et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999, 48:1113-1119.
209. Krssak M., Falk Petersen K., Dresner A., et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999, 42:113-116.
210. Unger R.H. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003, 144:5159-5165.
211. Kim S.F., Huang A.S., Snowman A.M., et al. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007, 104:3456-3459.
212. Sinclair D.A., Guarente L. Unlocking the secrets of longevity genes. Sci Am 294(3) 2006, 48-51:54-57.
213. Ruderman N.B., Carling D., Prentki M., Cacicedo J.M. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013, 123(7):2764-2772.
214. Lan F., Cacicedo J., Ruderman N., Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 2008, 283(41):27628-27635.
215. Hou X., et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008, 283(29):20015-20026.
216. Price N.L., Gomes A.P., Ling A.J., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012, 15(5):675-690.
217. Cantó C., Auwerx J. AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci 2010, 67(20):3407-3423.
218. Ruderman N.B., Xu X.J., Nelson L., et al. AMPK and SIRT1: a long-standing partnership?. Am J Physiol Endocrinol Metab 2010, 298(4):E751-E760.
219. Zang M., Xu S., Maitland-Toolan K.A., et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55(8):2180-2191.
220. Deleted in page proofs.
221. Ruderman N., Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 2004, 3:340-351.
222. Kola B., Christ-Crain M., Lolli F., et al. Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab 2008, 93(12):4969-4973.
223. La Montagna G., Cacciapuoti F., Buono R., et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res 2007, 4(2):130-135.
224. Deleted in page proofs.
225. Deleted in page proofs.
226. Sjostrom L., Peltonen M., Jacobson P., et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012, 307(1):56-65.
227. Bäckhed F., Manchester J.K., Semenkovich C.F., Gordon J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007, 104(3):979-984. 2007.
228. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
229. Cheal K.L., Abbasi F., Lamendola C., et al. Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004, 53:1195-1200.
230. McKeigue P.M., Pierpoint T., Ferrie J.E., et al. Relationship of glucose intolerance and hyperinsulinaemia to body fat pattern in south Asians and Europeans. Diabetologia 1992, 35:785-791.
231. Brunzell J.D., Ayyobi A.F. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003, 115(Suppl 8A):24S-28S.
232. Okamoto Y., Kihara S., Ouchi N., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
233. Yamauchi T., Kamon J., Waki H., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003, 278:2461-2468.
234. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
235. Isomaa B., Henricsson M., Almgren P., et al. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001, 44:1148-1154.
236. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
237. Alexander C.M., Landsman P.B., Teutsch S.M., Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52(5):1210-1214.
238. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414-419.
239. Grundy S.M. Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?. Am J Med 2007, 120:S3-S9.
240. Yu A.S., Keeffe E.B. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2002, 2:11-19.
241. Green R.M. NASH-hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003, 38:14-17.
242. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
243. Stefan N., Kantartzis K., Haring H.U. Causes and metabolic consequences of fatty liver. Endocr Rev 2008, 29:939-960.
244. Roberts E.A. Nonalcoholic steatohepatitis in children. Curr Gastroenterol Rep 2003, 5:253-259.
245. Petersen K.F., Dufour S., Savage D.B., et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007, 104:12587-12594.
246. Rabøl R., Petersen K.F., Dufour S., et al. Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc Natl Acad Sci U S A 2011, 108(33):13705-13709.
247. Legro R.S., Kunselman A.R., Dodson W.C., et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84:165-169.
248. Solomon C.G., Hu F.B., Dunaif A., et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002, 87:2013-2017.
249. Calle E.E., Thun M.J. Obesity and cancer. Oncogene 2004, 23:6365-6378.
250. Hawley S.A., Boudeau J., Reid J.L., et al. Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003, 2:28.
251. Woods A., Johnstone S.R., Dickerson K., et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003, 13:2004-2008.
252. Luo Z., Saha A.K., Xiang X., et al. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005, 26:69-76.
253. Motoshima H., Goldstein B.J., Igata M., et al. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006, 574:63-71.
254. Xiang X., Saha A.K., Wen R., et al. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004, 321:161-167.
255. Buzzai M., Jones R.G., Amaravadi R.K., et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007, 67(14):6745-6752.
256. Kramer A.F., Erickson K.I. Capitalizing on cortical plasticity: influence of physical activity on cognition and brain function. Trends Cogn Sci 2007, 11:342-348.
257. Patrone C., Eriksson O., Lindholm D. Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol 2014, 2(3):256-262.
258. Morris D. Cushing's syndrome. Endocrinology 2006, 429-464. Elsevier, Philadelphia. ed 5. L.J. De Groot (Ed.).
259. Seely W.W., Williams G.H. The cardiovascular system and endocrine disease. Principles and practice of endocrinology and metabolism 2001, 1857-1864. Lippincott Williams & Wilkins, Philadelphia. K.L. Becker (Ed.).
260. De leo M., Pivonello R., Auriemma R.S., et al. Cardiovascular disease in Cushing's syndrome: heart versus vasculature. Neuroendocrinology 2010, 92(Suppl 1):50-54.
261. Walker B.R. Is "Cushing's disease of the omentum" an affliction of mouse and men?. Diabetologia 2004, 47:767-769.
262. Sutinen J., Hakkinen A.M., Westerbacka J., et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther 2003, 8:199-207.
263. Unger R. How adipocytes integrate surplus caloric intake with caloric storage: lessons from Morgan Spurlock and some French geese. Curr Opin Endocrinol Diabetes Obes 2004, 11:251-257.
264. Sims E.A., Danforth E., Horton E.S., et al. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res 1973, 29:457-496.
265. Grundy S.M., Hansen B., Smith S.C., et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004, 109:551-556.
266. Skerrett P.J., Manson J.E. Exercise and diabetes prevention: reduction in risk of coronary heart disease in diabetes. Handbook of diabetes in exercise 2002, 155-182. American Diabetes Association, Alexandria VA. N. Ruderman, J.T. Devlin, S.H. Schneider, A. Kriska (Eds.).
267. Orchard T.J., Temprosa M., Goldberg R., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program Randomized Trial. Ann Intern Med 2005, 142:611-619.
268. Lindstrom J., Ilanne-Parikka P., Peltonen M., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679.
269. Yusuf S., Gerstein H., Hoogwerf B., et al. Ramipril and the development of diabetes. JAMA 2001, 286:1882-1885.
270. Robins S.J., Rubins H.B., Faas F.H., et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003, 26:1513-1517.
271. Hundal R.S., Krssak M., Dufour S., et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000, 49:2063-2069.
272. Zang M., Zuccollo A., Hou X., et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 2004, 279(46):47898-47905.
273. Madiraju A.K., Erion D.M., Rahimi Y., et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014, 510(7506):542-546.
274. UKPDS Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
275. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
276. Lin Y.C., Wu M.H., Wei T.T., et al. Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget 2014, 5(1):298-308.
277. Cheang W.S., Tian X.Y., Wong W.T., et al. Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5' adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway. Arterioscler Thromb Vasc Biol 2014, 34(4):830-836.
278. Almabrouk T.A., Ewart M.A., Salt I.P., Kennedy S. Perivascular fat, AMP-activated protein kinase and vascular diseases. Br J Pharmacol 2014, 171(3):595-617.
279. Boyle J.G., Logan P.J., Jones G.C., et al. AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia 2011, 54(7):1799-1809.
280. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
281. Lincoff A.M., Wolski K., Nicholls S.J., et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
282. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
283. Nissen S.E., Nicholls S.J., Wolski K., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008, 299:1561-1573.
284. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008, 29:1963-1972.
285. Ahmadian M., Suh J.M., Hah N., et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 2013, 19(5):557-566.
286. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
287. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
288. Shah R.V., Goldfine A.B. Statins and risk of new-onset diabetes mellitus. Circulation 2012, 126(18):e282-e284.
289. Rosenzweig J.L., Ferrannini E., Grundy S.M., et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3671-3689.
290. Cook S., Weitzman M., Auinger P., et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003, 157:821-827.
291. Berenson G.S., Srinivasan S.R., Bao W., et al. Associations between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998, 338:1650-1656.
292. Must A., Jacques P.F., Dallal G.E., et al. Long-term morbidity and mortality of overweight adolescents, A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 1992, 327:1350-1355.
293. Steinberger J., Daniels S.R. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 2003, 107:1448-1453.
294. Barker D.J., Hales C.N., Fall C.H., et al. Type 2 (noninsulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993, 36:62-67.
295. Phillips D.I. Birth weight and the future development of diabetes. A review of the evidence. Diabetes Care 1998, 21(Suppl 2):B150-B155.
296. Bhargava S.K., Sachdev H.S., Fall C.H., et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med 2004, 350:865-875.
297. Heijmans B.T., Tobi E.W., Stein A.D., et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A 2008, 105(44):17046-17049.
298. Schulz L.C. The Dutch Hunger Winter and the developmental origins of health and disease. Proc Natl Acad Sci U S A 2010, 107(39):16757-16758.
299. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
300. Neel J.V. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"?. Am J Hum Genet 1962, 14:353-362.
301. Hu Z., Cha S.H., Chohnan S., et al. Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc Natl Acad Sci U S A 2003, 100:1262-12629.
302. Kemp B.E., Stapleton D., Campbell D.J., et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 2003, 31:162-168.
303. Hardie D.G., Scott J.W., Pan D.A., et al. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 2003, 546:113-120.
304. Sanders M.J., Grondin P.O., Hegarty B.D., et al. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 2007, 403:139-148.
305. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100:328-341.